Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Sep 2025 value amounting to $26.6 million.

  • Lineage Cell Therapeutics' Gains from Investment Securities was N/A to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.8 million, marking a year-over-year change of. This contributed to the annual value of -$2.1 million for FY2024, which is 4040.74% down from last year.
  • Lineage Cell Therapeutics' Gains from Investment Securities amounted to $26.6 million in Q3 2025, which was up 108.45% from $12.7 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Gains from Investment Securities ranged from a high of $26.6 million in Q3 2025 and a low of -$2.3 million during Q1 2025.
  • In the last 3 years, Lineage Cell Therapeutics' Gains from Investment Securities had a median value of $18,000 in 2023 and averaged $4.4 million.
  • In the last 5 years, Lineage Cell Therapeutics' Gains from Investment Securities skyrocketed by 78.36% in 2021 and then tumbled by 16,776.92% in 2024.
  • Lineage Cell Therapeutics' Gains from Investment Securities (Quarterly) stood at -$29,000 in 2021, then reached $13,000 in 2023, then plummeted by 16,776.92% to -$2.2 million in 2024, then plummeted by 10,121.74% to $26.6 million in 2025.
  • Its Gains from Investment Securities was $26.6 million in Q3 2025, compared to $12.7 million in Q2 2025 and -$2.3 million in Q1 2025.